DE60207278D1 - Attenuierte bakterien verwendbar als impstoffe - Google Patents

Attenuierte bakterien verwendbar als impstoffe

Info

Publication number
DE60207278D1
DE60207278D1 DE60207278T DE60207278T DE60207278D1 DE 60207278 D1 DE60207278 D1 DE 60207278D1 DE 60207278 T DE60207278 T DE 60207278T DE 60207278 T DE60207278 T DE 60207278T DE 60207278 D1 DE60207278 D1 DE 60207278D1
Authority
DE
Germany
Prior art keywords
attenuated
bacteria
imports
attenuated bacteria
enterotoxins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60207278T
Other languages
English (en)
Other versions
DE60207278T3 (de
DE60207278T2 (de
Inventor
Arthur K Turner
Judith Greenwood
Jonathan C Stephens
Juliet C Beavis
Michael J Darsley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Holding Ltd
Original Assignee
Acambis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9921935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60207278(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acambis Research Ltd filed Critical Acambis Research Ltd
Publication of DE60207278D1 publication Critical patent/DE60207278D1/de
Application granted granted Critical
Publication of DE60207278T2 publication Critical patent/DE60207278T2/de
Publication of DE60207278T3 publication Critical patent/DE60207278T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60207278T 2001-09-11 2002-09-11 Attenuierte bakterien verwendbar als impfstoff Expired - Lifetime DE60207278T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0121998 2001-09-11
GBGB0121998.9A GB0121998D0 (en) 2001-09-11 2001-09-11 Attenuated bacteria useful in vaccines
PCT/GB2002/004164 WO2003022307A1 (en) 2001-09-11 2002-09-11 Attenuated bacteria useful in vaccines

Publications (3)

Publication Number Publication Date
DE60207278D1 true DE60207278D1 (de) 2005-12-15
DE60207278T2 DE60207278T2 (de) 2006-08-10
DE60207278T3 DE60207278T3 (de) 2011-05-05

Family

ID=9921935

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60207277T Revoked DE60207277T2 (de) 2001-09-11 2002-09-11 Bakterieller impfstoff
DE60207278T Expired - Lifetime DE60207278T3 (de) 2001-09-11 2002-09-11 Attenuierte bakterien verwendbar als impfstoff

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60207277T Revoked DE60207277T2 (de) 2001-09-11 2002-09-11 Bakterieller impfstoff

Country Status (10)

Country Link
US (4) US7943122B2 (de)
EP (2) EP1425037B1 (de)
AT (2) ATE308992T1 (de)
AU (2) AU2002321644B2 (de)
CA (2) CA2460025A1 (de)
DE (2) DE60207277T2 (de)
DK (2) DK1425037T3 (de)
ES (2) ES2256515T5 (de)
GB (1) GB0121998D0 (de)
WO (2) WO2003022307A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7468269B2 (en) * 2003-02-26 2008-12-23 University Of Massachusetts Reagents for recombinogenic engineering and uses thereof
GB0325494D0 (en) * 2003-10-31 2003-12-03 Sbl Vaccin Ab Expression system
EP1543836A1 (de) * 2003-12-17 2005-06-22 Berna Biotech AG Rekombinante Stamm von Vibrio cholerae und Impfstoff, der diesem Stamm enthält
WO2005113827A2 (en) * 2004-05-19 2005-12-01 THE UNITED STATES OF AMERICA AS REPRESENTED BY THESECRETARY OF THE ARMY, Walter REED ARMY INSTITUTE OF RESEARCH Construction of live attenuated shigella vaccine strains that express cfa/i antigens (cfab and cfae) and the b subunit of heat-labile enterotoxin (ltb) from enterotoxigenic e. coli
AU2006205128B2 (en) 2005-01-11 2013-03-28 The United States Of America As Represented By The Secretary Of The Navy Adhesin as immunogen against Escherichia coli
FR2890859B1 (fr) * 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
CN101378780A (zh) * 2006-02-01 2009-03-04 Sbl疫苗公司 重组细菌中的肠产毒性大肠杆菌定居因子(cf)抗原
BRPI0813428A2 (pt) * 2007-07-02 2014-12-23 Crucell Sweden Ab Óperon recombinante, método para produzir uma célula hospedeira, composição de vacina contra diarréia, e, uso de um óperon
US9410157B2 (en) * 2010-07-30 2016-08-09 Wisconsin Alumni Research Foundation Systems and methods for the secretion of recombinant proteins in gram negative bacteria
DK2750701T3 (en) 2011-09-12 2016-01-11 Scandinavian Biopharma Holding Ab PROCEDURE FOR INCREASING ETEC-CS6 ANTIGEN PRESENTATION ON CELL SURFACE AND THEREFORE AVAILABLE PRODUCTS
EP2897638A1 (de) 2012-09-24 2015-07-29 Montana State University-Bozeman Rekombinanter lactococcus lactis zur expression des escherichia coli-kolonisationsfaktor-antigens i (cfa/i) fimbriae und verfahren zu deren verwendung
AU2013345316B2 (en) 2012-11-19 2016-04-14 The United States Of America As Represented By The Secretary Of The Navy Recombinant polypeptide construct comprising multiple enterotoxigenic Escherichia coli fimbrial subunits
US10500261B2 (en) 2014-11-05 2019-12-10 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
CA2966754A1 (en) 2014-11-05 2016-05-12 The United States Of America As Represented By The Secretary Of The Navy Synthetic antigen constructs against campylobacter jejuni
CN105063073A (zh) * 2015-09-16 2015-11-18 中国科学院南海海洋研究所 一种弧菌通用的基因敲除自杀载体及其应用
JP2021519789A (ja) * 2018-04-03 2021-08-12 ユニバーシティ オブ メリーランド，ボルチモア 増強された多価赤痢菌−毒素原性大腸菌ワクチン

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58146596A (ja) * 1982-02-25 1983-09-01 Takeda Chem Ind Ltd 組換えｄｎａ、それで形質転換させた微生物およびそれらの用途
US4935364A (en) 1983-03-04 1990-06-19 Swiss Serum And Vaccine Institute Berne Method of isolating restriction fragment deletions in vibrio cholerae and products thereof
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
SE9100556D0 (sv) 1991-02-26 1991-02-26 Holmgren Jan Preparation and use of formalin-killed colonization-factor-antigen (cfa)-expressing e coli organisms for vaccination against enteric infection/diarrhea caused by enterotoxigenic e coli bacteria in humans
PL170938B1 (pl) 1991-03-05 1997-02-28 Wellcome Found Sposób wytwarzania szczepionki przeciwko infekcjom Salmonella PL PL
US7118758B1 (en) * 1997-01-24 2006-10-10 The United States Of America As Represented By The Secretary Of The Army Transformed bacteria producing CS6 antigens as vaccines
US6019982A (en) 1994-08-26 2000-02-01 The Administrators Of The Tulane Educational Fund Mutant enterotoxin effective as a non-toxic oral adjuvant
US6682729B1 (en) * 1995-05-03 2004-01-27 University Of Maryland, Baltimore Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same
US7404961B2 (en) * 1996-08-02 2008-07-29 The United States Of America As Represented By The Secretary Of The Army Peptides responsive to antibodies against consensus peptide of the CS4-CFA/I family proteins
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
SE9801852D0 (sv) 1998-05-26 1998-05-26 Sbl Vaccin Ab Method of producing thy A-strains of Vibro cholerae, suck strains and their use
SE515285C2 (sv) * 1998-12-18 2001-07-09 Sbl Vaccin Ab Oralt vaccin mot diarré
US7722887B1 (en) * 1999-09-15 2010-05-25 Mogam Biotechnology Research Institute Detoxified mutants of escherichia coli heat-labile enterotoxin
ATE349531T1 (de) * 2000-04-20 2007-01-15 Univ Maryland Isolierung und charakterisierung des csa-operons (etec-cs4 pili) und verfahren zu dessen anwendung
GB0121998D0 (en) * 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
WO2007117339A2 (en) * 2006-01-11 2007-10-18 The United States Of America As Respresented By The Secretary Of The Navy Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
US20120064114A1 (en) * 2008-10-21 2012-03-15 Emergent Product Development United Kingdom Use of e. coli surface antigen 3 sequences for the export of heterologous antigens
WO2011002836A2 (en) * 2009-06-30 2011-01-06 Stc.Unm Attenuated enterohemorrhagic e.coli-based vaccine vector and methods relating thereto

Also Published As

Publication number Publication date
AU2002321644B2 (en) 2008-03-13
EP1425038A1 (de) 2004-06-09
ES2256515T3 (es) 2006-07-16
US7951361B2 (en) 2011-05-31
ES2256515T5 (es) 2011-02-25
EP1425037B1 (de) 2005-11-09
DE60207278T3 (de) 2011-05-05
CA2459586A1 (en) 2003-03-20
EP1425038B2 (de) 2010-09-01
US20110189225A1 (en) 2011-08-04
DK1425038T4 (da) 2010-12-13
EP1425038B1 (de) 2005-11-09
CA2460025A1 (en) 2003-03-20
ATE308991T1 (de) 2005-11-15
DE60207277T2 (de) 2006-08-03
WO2003022306A2 (en) 2003-03-20
DK1425038T3 (da) 2006-03-27
US7943122B2 (en) 2011-05-17
GB0121998D0 (en) 2001-10-31
ATE308992T1 (de) 2005-11-15
DE60207278T2 (de) 2006-08-10
AU2002321652B2 (en) 2008-04-10
WO2003022306A3 (en) 2003-06-26
ES2256514T3 (es) 2006-07-16
US20110200638A1 (en) 2011-08-18
DE60207277D1 (de) 2005-12-15
US20050054075A1 (en) 2005-03-10
US20040253710A1 (en) 2004-12-16
US8318148B2 (en) 2012-11-27
EP1425037A2 (de) 2004-06-09
WO2003022307A1 (en) 2003-03-20
DK1425037T3 (da) 2006-03-27

Similar Documents

Publication Publication Date Title
DE60207278D1 (de) Attenuierte bakterien verwendbar als impstoffe
WO2002053189A3 (en) Immunogenic complex
ATE357249T1 (de) Auf bläschen basierendes impfstoff gegen chlamydia
CY1111119T1 (el) Φαρμακευτικα σκευασματα που περιλαμβανουν κολλοειδες διοξειδιο του πυριτιου
DK1353689T3 (da) Immuniseringspræparater og anvendelse deraf
BR0108711A (pt) Expressão heteróloga de proteìnas de neisseria
NO983876L (no) Syntetiske HIV-gener
WO2006123155A3 (en) Vaccine composition comprising b-subunit of e. coli heat toxin and an atigen and an adjuvant
SI1618128T1 (sl) Cepivo proti tuberkolozi z izboljšano učinkovitostjo
NO20004781D0 (no) Svekkede bakterier anvendelige i vaksiner
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
ATE413888T1 (de) Salmonella vakzine
WO2006113907A3 (en) Escherichia coli o157:h7 proteins and uses thereof
DK1154791T3 (da) Neisseria-vaccinesammensætninger og fremgangsmåder
NO20025329L (no) Virulensgener, proteiner og deres anvendelse
ATE504312T1 (de) Hybrid-toxine mit shiga-artigen toxin- untereinheiten, verbunden mit escherichia coli wärmeinstabilen enterotoxin-untereinheiten und vakzine daraus
ATE408013T1 (de) Infektiöses cdna klon des gb-virus b und dessen verwendungen
WO2001032697A3 (en) Virulence genes and proteins from brucella melitensis, and their use
DE60032293D1 (de) Lebende attenuierte bakterien zur verwendung als impfstoff
ATE313628T1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
RU2003110247A (ru) Штамм escherichia coli б-5, используемый для получения термолабильного экзотоксина
DE60126765D1 (de) Virulenz gene, proteine, und ihre verwendung
CY1117291T1 (el) Εμβολιο κατα του ροταϊου
김영구 Y00KKMY0MS
RU2002127716A (ru) Ассоциированная вакцина против сибирской язвы и некробактериоза животных

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings